Onco T Ab
Biotechnology, 9201 University City BLVD, Charlotte, North Carolina, 28223, United States, 1-10 Employees
Who is ONCOTAB
OncoTAb, Inc., a North Carolina based biotechnology company, was founded by Mayo Clinic alumna Dr. Pinku Mukherjee, with a mission to improve the quality of cancer care by addressing unme...
Read More
- Headquarters: 9201 University City BLVD, Charlotte, North Carolina, 28223, United States
- Date Founded: 2011
- Employees: 1-10
- Revenue: $1 Million to $5 Million
- Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8221 | NAICS Code: 62 | Show More
OncoTAb Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding OncoTAb
Answer: OncoTAb's headquarters are located at 9201 University City BLVD, Charlotte, North Carolina, 28223, United States
Answer: OncoTAb's official website is https://oncotab.com
Answer: OncoTAb's revenue is $1 Million to $5 Million
Answer: OncoTAb's SIC: 8221
Answer: OncoTAb's NAICS: 62
Answer: OncoTAb has 1-10 employees
Answer: OncoTAb is in Biotechnology
Answer: OncoTAb contact info: Phone number: Website: https://oncotab.com
Answer: OncoTAb, Inc., a North Carolina based biotechnology company, was founded by Mayo Clinic alumna Dr. Pinku Mukherjee, with a mission to improve the quality of cancer care by addressing unmet cancer diagnostic and therapeutic needs. The company has just launched its first product: AgkuraTM Personal Score a simple, non-invasive blood test that aids breast cancer detection in women with dense breast tissue. Roughly half of the women in the US have dense breast tissue and mammograms miss 50% of the breast cancers in these women, resulting in late stage diagnosis and mortality. AgkuraTM Personal Score measures the biomarker tumor-associated MUC1 (tMUC1) and shows a trend of increasing value from benign disease through breast cancer stages 1 to 4. Women can monitor their personal score in conjunction with annual mammograms. A score above the normal range or an increase greater than normal variation will trigger a recommendation for diagnostic imaging (ultrasound or MRI), resulting in earlier stage diagnosis of breast cancer. The company is also working on developing treatments for breast and pancreatic cancers.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month